CD30 is also expressed on subsets of non-Hodgkin’s lymphoma, including ALCL and CTCL, and on rare solid tumors such as germ-line malignancies.7 ADCETRIS® consists of three components: (1) the chimeric antibody cAC10, specific for human CD30; (2) the potent antimicrotubule agent monomethyl auristatin E (MMAE); and (3) a protease-cleavable linker that covalently attaches MMAE to cAC10.11–13 The biological activity of ADCETRIS results from a multistep process. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.